News | February 18, 2008

Statin Pretreatment Improves Myocardial Perfusion Post Angioplasty

February 19, 2008 - Among patients with acute myocardial infarction (AMI), prior statin therapy is associated with better perfusion after primary angioplasty of the infarct-related artery, according to a report in the January 15 issue of the American Journal of Cardiology.

Recent studies have demonstrated the benefits of statin therapy on endothelial function, inflammation, and platelet activation in patients with stable atherosclerosis, the authors point out.

Rainer Hoffmann, M.D., and colleagues from University Hospital RWTH, Aachen, Germany, sought to determine whether pretreatment with statins decreased inflammatory activity and improved myocardial perfusion in 253 consecutive patients undergoing primary angioplasty within 12 hours of AMI.

The 86 patients who had been taking a statin for at least a week before the MI were more likely to show normal myocardial perfusion and less likely to show impaired perfusion after angioplasty than were the 167 control patients, the investigators report.

Statin-treated patients had a lower frequency of increased C-reactive protein level on admission compared with control patients.

Independent predictors of normal myocardial perfusion in a multivariate regression analysis included age of 70 years or less, non-increased C-reactive protein, and statin pretreatment.

"This was not a prospective randomized study," the researchers noted. "However, unless a large population-based study is performed, it will be impossible to define in a randomized fashion the impact of statin pretreatment for patients developing AMI because of the relatively low incidence of AMI in a healthy population."

For more information: www.ajconline.org


Related Content

News | Balloon Catheter

June 13, 2024 — The U.S. Food and Drug Administration (FDA) announced that Teleflex, and their subsidiary Arrow ...

Home June 13, 2024
Home
News | Balloon Catheter

April 4, 2024 — The U.S. Food and Drug Administration (FDA) announced that Medos International Sàrl is recalling ...

Home April 04, 2024
Home
News | Balloon Catheter

January 18, 2024 — Summa Therapeutics, LLC announced that the first-in-man injectable angioplasty procedures for ...

Home January 18, 2024
Home
News | Balloon Catheter
Cardiovascular Systems, Inc., a medical device company developing and commercializing innovative interventional ...
Home February 25, 2022
Home
News | Balloon Catheter

February 15, 2022 – CERENOVUS, an emerging leader in neurovascular care and part of Johnson & Johnson Medical Devices ...

Home February 15, 2022
Home
News | Balloon Catheter

May 20, 2021 — Boston Scientific Corporation announced it has initiated the AGENT IDE trial for the Agent Drug-Coated ...

Home May 20, 2021
Home
Feature | Balloon Catheter | By Dave Fornell, Editor

The first devices developed for interventional cardiology were percutaneous transluminal coronary angioplasty (PTCA) ...

Home March 16, 2021
Home
Feature | Balloon Catheter

February 17, 2021 — The U.S. Food and Drug Administration (FDA) has cleared Shockwave Medical's Intravascular ...

Home February 17, 2021
Home
News | Balloon Catheter

June 4, 2020 — Transit Scientific announced the U.S. Food and Drug Administration (FDA) cleared the XO Score ...

Home June 04, 2020
Home
News | Balloon Catheter

February 24, 2020 — Abbott has voluntarily recalled specific lots of two types of its coronary angioplasty catheters — ...

Home February 24, 2020
Home
Subscribe Now